Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in the USA / NCT07652047
Recruiting Phase 1

A Study to Evaluate the Safety and Tolerability of Different Doses of CX11 Tablets

NCT07652047 · tracked via the Priya Life Science USA tracker
Sponsor
Corxel Pharmaceuticals
Phase
Phase 1
Started
2026-05-11
Last updated
2026-06-17

Condition(s) studied

Obesity & Overweight

Investigational drug(s) / intervention(s)

CX11 →PlaceboCX11 →

CX11: CX11 tablets administered orally once daily (QD) with meals

Placebo: Matching placebo tablets administered orally once daily (QD) with meals

CX11: CX11 tablets administered orally once daily (QD) with high fat, high calorie meal

Study summary

A multi-center, randomized, placebo-controlled, double-blinded (within cohorts), Sponsor-unblinded, Phase 1b study to explore the safety, pharmacokinetics, and pharmacodynamics of CX11 tablets in participants with obesity or overweight with weight-related comorbidities.

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
55 Years
Healthy volunteers
No
Inclusion Criteria: * Male or female, 18-55 years. * BMI ≥30.0 to ≤39.9 kg/m², or ≥27.0 to \<30.0 kg/m² with at least 1 weight-related comorbidity: prediabetes, hypertension, dyslipidemia, or obstructive sleep apnea. * Prior unsuccessful diet/exercise weight-loss attempt and stable body weight within 90 days. * Able to comply with study procedures and reproductive requirements. Exclusion Criteria: * Diabetes or obesity due to endocrine/genetic causes. * Recent weight-loss drugs, GLP-1-based therapy, glucose-lowering drugs, obesity surgery/device, or investigational treatment. * Significant cardiovascular, ECG/QT, pancreatic, gallbladder, GI, liver, kidney, thyroid, psychiatric, malignant, infectious, autoimmune, or lab abnormality risks. * Personal/family history of medullary thyroid carcinoma or multiple endocrine neoplasia. * Pregnancy, breastfeeding, recent nicotine/drug use, excessive alcohol use, or any condition/medication making participation inappropriate.

Primary outcome measure(s)

  • Percentage change in body weight from baseline — Week 26

Trial sites (2)

FacilityCityRegionStatus
Corxel Investigational site Las Vegas Nevada Recruiting
Corxel Investigational Site Austin Texas Recruiting

More Corxel Pharmaceuticals trials in the USA

Optimizing Reperfusion to Improve Outcomes and Neurologic Function Recruiting
A Study of CX11 Tablets in Patients With Type 2 Diabetes Mellitus Recruiting

Other trials for the same condition

Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss Active, not recruiting
Evaluation of a Mobile Wellness Application and Wearable Fitness Tracker on Weight Management and Health Outcomes Starting soon
A Proof-of-Concept Study to Evaluate Topical-Lingual Semaglutide in Adults With Obesity Recruiting
Safety and Tolerability of a Nutritional Formula Designed to Aid in Maintenance of Muscle During Periods of Caloric Restriction in Adults Starting soon
A Phase 2A Clinical Trial to Assess the Safety and Tolerability of ERX1000 in Men and Women for the Treatment of Obesity. Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07652047 on ClinicalTrials.gov ↗ ← All trials in the USA